Redx has presented pre-clinical data for its newly nominated development candidate RXC006 which suggests it has great potential for treatment of fibrosis.
RXC006, a novel inhibitor of the porcupine enzyme, will be developed as an orally administered, first-in-class treatment for the orphan disease, idiopathic pulmonary fibrosis (IPF).
IPF is a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options.
The company said it expects to commence first-in-man studies with RXC006 during 2020.
In the first public disclosure of data on RXC006, RXC006 was shown to be highly effective at suppressing the Wnt pathway (porcupine sits on the Wnt pathway) and that RXC006 was able to suppress lung fibrosis, in vivo.
Suppression of fibrosis has also been shown in animal models of both liver and kidney fibrosis.
More specifically, it was shown that RXC006 was able to suppress the release of Wnt-5a (another protein on the Wnt pathway) from human lung fibroblasts at nanomolar concentrations and reduce fibroblast activation. In two separate mouse models of disease, RXC006 strongly reduced collagen deposition and significantly impacted Ashcroft scores (a validated scale for estimating the severity of pulmonary fibrosis), when dosed therapeutically.
Dr Richard Armer, Chief Scientific Officer, Redx Pharma, said: “The data suggests that RXC006 has great potential to treat fibrosis in human patients.
“Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.”